| Dr Joshua Sturm, MD PHD | |
|
135 Rutledge Ave Ste 1130, Charleston, SC 29425-3720 | |
| (843) 876-0791 | |
| (843) 792-0546 |
| Full Name | Dr Joshua Sturm |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 7 Years |
| Location | 135 Rutledge Ave Ste 1130, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184146359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 88376 (South Carolina) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Musc Medical Center | Charleston, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Medical Associates Of The Medical University Of South Carol | 6305758574 | 1297 |
News Archive
A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
Little is known about the impact of early aggressive regional analgesia on short- and long-term pain and psychological outcomes of soldiers with major combat injuries.
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
The Centers for Medicare & Medicaid Services chief Marilyn Tavenner discussed health exchanges, among other things, with Georgia Health News. Other news outlets detailed the exchange developments in Minnesota and Colorado.
› Verified 9 days ago
| Entity Name | University Medical Associates Of The Medical University Of South Carol |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043241110 PECOS PAC ID: 6305758574 Enrollment ID: O20031105000291 |
News Archive
A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
Little is known about the impact of early aggressive regional analgesia on short- and long-term pain and psychological outcomes of soldiers with major combat injuries.
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
The Centers for Medicare & Medicaid Services chief Marilyn Tavenner discussed health exchanges, among other things, with Georgia Health News. Other news outlets detailed the exchange developments in Minnesota and Colorado.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua Sturm, MD PHD Po Box 751461, Charlotte, NC 28275-1461 Ph: (843) 792-6200 | Dr Joshua Sturm, MD PHD 135 Rutledge Ave Ste 1130, Charleston, SC 29425-3720 Ph: (843) 876-0791 |
News Archive
A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
Little is known about the impact of early aggressive regional analgesia on short- and long-term pain and psychological outcomes of soldiers with major combat injuries.
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
The Centers for Medicare & Medicaid Services chief Marilyn Tavenner discussed health exchanges, among other things, with Georgia Health News. Other news outlets detailed the exchange developments in Minnesota and Colorado.
› Verified 9 days ago
Jenna Hanner Barengo, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 740-525-0170 | |
Ronald James Mcvicar, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1849 Savage Rd, Charleston, SC 29407 Phone: 843-766-7103 Fax: 843-576-2692 | |
Nicole Kloosterman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave # Msc550, Charleston, SC 29425 Phone: 843-792-8299 | |
Dr. Mark Drury Ghegan, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1849 Savage Rd, Charleston, SC 29407 Phone: 843-766-7103 Fax: 843-763-3834 | |
Anthony Ghanem, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 135 Rutledge Ave Ste 1130, Charleston, SC 29425 Phone: 843-876-0791 Fax: 843-792-0546 | |
Dr. David Watson Rodwell Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 67 Broad St, Suite 200, Charleston, SC 29401 Phone: 843-628-1415 | |
Ted Meyer, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |